Skip to main content

Use of Gonadotropin-Releasing Hormone (GnRH) Agonists in Patients with Gender Dysphoria: A Descriptive Analysis

Basic Details
Date Posted
Status
Complete
Medical Product
gonadotropin-releasing hormone agonists
Health Outcome(s)
duration of use
Description

In this report we examined counts and follow-up time for individuals with a diagnosis of gender dysphoria in the Merative™ MarketScan® Research Databases. In addition, we examined counts of individuals using gonadotropin-releasing hormone (GnRH) agonists with or without an inclusion requirement for a diagnosis of gender dysphoria before their GnRH agonist exposure.

The study period includes data from October 1, 2015 to June 30, 2021. We queried the  Merative™ MarketScan® Research Databases on October 5, 2022.

Deliverables (1)
Sentinel Modular Program Report: Use of Gonadotropin-Releasing Hormone (GnRH) Agonists in Patients with Gender Dysphoria: A Descriptive Analysis
Additional Details
FDA Center
CDER
Time Period
October 1, 2015 - June 30, 2021
Analysis Type
Descriptive
Population / Cohort
Individuals 12 to 20 years of age
Data Sources
Merative™ MarketScan® Research Databases
Related Links
Drug Study: Gonadotropin Releasing Hormone (GnRH) Agonists & Utilization Characterization